ID
42247
Description
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872
Lien
https://clinicaltrials.gov/ct2/show/NCT00391872
Mots-clés
Versions (3)
- 28/11/15 28/11/15 -
- 14/4/21 14/4/21 - Ahmed Rafee, MD
- 15/4/21 15/4/21 - Ahmed Rafee, MD
Détendeur de droits
AstraZeneca
Téléchargé le
15 de abril de 2021
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Excerpt PLATO Acute coronary Syndrome NCT00391872
Section Investigational Products
Similar models
Section Investigational Products
C1608718 (UMLS CUI [1,2])
C1608718 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
C0070166 (UMLS CUI [1,2])
Aucun commentaire